Company Overview and News
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Amazon (AMZN), Broadcom (AVGO) and Lockheed Martin (LMT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFCNP LMT BCE AVGO WFC STT UPS
We've touched upon homebuilders and constructors (PKB, XHB, ITB, AIRR) at the beginning of this week, yet it feels like it was ages ago... Well, from a performance perspective - it is!
The market expects State Street (STT - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
Muted trading business is unlikely to support Goldman Sachs’ (GS - Free Report) third-quarter 2018 earnings, to be reported on Oct 16. After an impressive first-half 2018 performance driven by significant volatility, client activity remained low in the third quarter. Therefore, trading revenues are feared to have been negatively impacted. Being an investment bank, Goldman is exposed to extreme market volatility.
CBSH GS GLSSP STT JBK CBSHP CMA GSC TFG GSJ CBCB GJS
The earnings season is just around the corner and investors are keen to see if major banks can replicate or beat their solid first-half 2018 financial performance. Major bank stocks have been struggling constantly over investors’ concerns related to the flattening of the yield curve and increase in deposit betas. As such, net interest margin (one of the key metrics for gauging banks’ profitability) is expected to be subdued in the third quarter despite rise in interest rates (in June and September).
WFCNP CMPWW WFC STT CMA BK
Citigroup (C - Free Report) is scheduled to report third-quarter earnings, before the opening bell on Oct 12. After impressive second-quarter 2018 results, driven by consumer banking business, volatility-driven fixed income and equity trading revenues are likely to have remained flat to slightly higher on a year-over-year basis in the third quarter. Per John Gerspach, chief financial officer (CFO) of Citigroup, the third quarter may have been partly negatively impacted by seasonal slowdown due to the summer months.
STT C CMA
In a new study by Harvard Business School scholars looks into the performance of LPs invested with private equity over four decades.
The People’s Bank of China is among central banks that have been adding gold to their reserves over the past several years, according to the World Gold Council. The Chinese central bank is aiming to diversify its reserve assets and hold the precious metal as a form of currency as well as store of value.
Marathon Oil has built an attractive oil and gas production portfolio in four major U.S. basins: Bakken, Eagle Ford, STACK/SCOOP, and Permian. It also has some overseas operations.
STT MQBKY BOE WPXP WLL SM CTLR MCQEF AXAS MPC WPX EV EOG OAS WTI MRO CLR MQG
Average Annual Total Returns (09/30/18) Since Inception (11/01/95) 10.08% 10–year 7.51% 5–year 6.99% 1–year 5.29% 3–month 2.46% Gross Expense Ratio as of 09/30/17 was 0.87% Net Expense Ratio as of 09/30/17 was 0.78%
FLEX NOV CVS NKE HCA DOV STT BAC PDCE BHGE ARNC BWA WFCNP PM DOV.WI TEL BAC CHTR LEA GM ORCL WFC MA BHI OCLCF UNH
Average Annual Total Returns (09/30/18) Since Inception (08/05/91) 12.89% 10–year 13.11% 5–year 12.57% 1–year 11.84% 3–month 4.24% Gross Expense Ratio as of 09/30/17 was 0.90% Net Expense Ratio as of 09/30/17 was 0.86%
STT CSC GE GEC AAL NFLX HCA AAPL GNE DXC.WI DXC
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET